Corcept Therapeutics Incorporated (CORT)

About Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

As of November 3, 2026, Corcept Therapeutics Incorporated (CORT) stock climbed to $83.53, up 3.82% (+$3.08) versus the previous close. On the day, shares have traded between $80.92 and $84.06. That puts CORT around the middle of its 52-week range of $28.66 to $126.38. Corcept Therapeutics Incorporated operates in the pharmaceutical preparations space and carries a market capitalization of roughly $8.70 billion, with about 772.8K shares changing hands.

Latest CORT news

• Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference CallYahoo Finance· Oct 27, 4:05 PM ET
• What Corcept Therapeutics Stock Positive Trial Results Mean For ShareholdersYahoo Finance· Oct 26, 7:31 PM ET
• Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian CancerYahoo Finance· Oct 26, 8:00 AM ET
• Can Corcept Therapeutics Stock Rally 40% After This Dip?trefis.com· Oct 26, 3:11 AM ET
• Genmab stock surges 9% following positive phase 3 ovarian cancer trial resultsYahoo Finance· Oct 23, 12:44 PM ETGMAB
• 2 cash-producing stocks to research further and 1 we find riskyYahoo Finance· Oct 22, 1:33 PM ET
• 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 DiabetesYahoo Finance· Oct 20, 4:00 PM ETEASD
• Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?Yahoo Finance· Oct 19, 8:50 AM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want CORT headlines, alerts and AI research in one place? Create a free account →

• That size on the May 105s is real conviction. I like the setup only if $CORT holds above the recent base, otherwise that flow gets trapped fast. Watch how it trades into the close.

  @TopOptionsAIerts· Nov 2, 3:47 PM ET

• $471K bought of the $CORT May 21st $105 call 🟢

  @peloswing· Nov 2, 3:44 PM ET

• $CORT closed the week at $81.12 (-5.5% w/w, -5.6% Friday), below the 50-day SMA ($111.98) and above the 200-day ($74.77). RSI14 23.1. Support $80.28, resistance $122.81 (20-day range, bottom). Broad market sell-off on Friday. New hub updated: https://www.merlintrader.com/corce…

  @Merlintrader· Oct 31, 3:00 PM ET

• $CORT 🤓 gap or squeeze

  @moneybag888· Oct 31, 11:37 AM ET· Bullish

• $CORT 4th of November

  @Dimon11· Oct 30, 2:13 PM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →